Bilateral endoscopic sealant lung volume reduction therapy for advanced emphysema

Area of Science:

• Pulmonary Medicine
• Interventional Pulmonology
• Medical Device Technology

Background:

• Advanced emphysema poses significant challenges for patient quality of life and respiratory function.
• Current treatment options for advanced emphysema have limitations.

Purpose of the Study:

• To assess the safety and efficacy of bilateral AeriSeal Emphysematous Lung Sealant System (ELS) treatment in patients with advanced emphysema.
• To evaluate treatment outcomes up to one year post-procedure.

Main Methods:

• Twenty patients with advanced emphysema received bilateral ELS treatment targeting four subsegments (two in each upper lobe).
• Treatments were administered under moderate sedation.
• Efficacy was assessed using quantitative CT scans, spirometry, gas trapping measurements, diffusing capacity, symptom scores, and quality of life questionnaires at 3, 6, and 12 months.

Main Results:

• The primary endpoint of reduced upper lobe lung volume at 3 months was achieved (-895 ± 484 mL, P < .001).
• Significant improvements were observed in spirometry (FEV1), gas trapping (RV/TLC), diffusing capacity (DLCO), dyspnea scores (MRC), and quality of life (SGRQ) at 6 and 12 months.
• The procedure was associated with short procedure times (15.2 ± 9.6 min) and brief hospital stays (1.1 days).

Conclusions:

• Bilateral ELS treatment is a safe and effective option for patients with advanced emphysema.
• The treatment leads to short procedure times and hospital stays.
• Physiologic and functional improvements are sustained up to one year post-treatment.